Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Return on Sales (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Return on Sales data on record, last reported at 1.15% in Q3 2025.

  • For Q3 2025, Return on Sales rose 466.0% year-over-year to 1.15%; the TTM value through Sep 2025 reached 1.27%, up 454.0%, while the annual FY2022 figure was 86.98%, 7297.0% down from the prior year.
  • Return on Sales reached 1.15% in Q3 2025 per CYCN's latest filing, up from 17.98% in the prior quarter.
  • Across five years, Return on Sales topped out at 22.52% in Q1 2023 and bottomed at 216.05% in Q1 2021.
  • Average Return on Sales over 5 years is 28.11%, with a median of 17.98% recorded in 2025.
  • Peak YoY movement for Return on Sales: tumbled -19610bps in 2021, then skyrocketed 19779bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 26.9% in 2021, then plummeted by -132bps to 62.42% in 2022, then skyrocketed by 96bps to 2.41% in 2023, then surged by 112bps to 0.28% in 2024, then plummeted by -514bps to 1.15% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 1.15% in Q3 2025, 17.98% in Q2 2025, and 17.99% in Q1 2025.